

SIgN affiliated publications by Wang Liang Wei

Last updated: 26 Feb 2025

2025

Yee TM, Wang LW. Metabolic Reprogramming in Epstein-Barr Virus Associated Diseases. *J Med Virol*. 2025 Feb;97(2):e70197.

2024

Lee WWL, Lim JQ, Tang TPL, Tan D, Koh SM, Puan KJ, Wang LW, Lim J, Tan KP, Chng WJ, Lim ST, Ong CK and Rotzschke O. Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma. *Front. Immunol.*, 12 April 2024 Volume 15 - 2024

2023

Leung NYT, **Wang LW[†]**. Targeting Metabolic Vulnerabilities in Epstein-Barr Virus-Driven Proliferative Diseases. *Cancers*. 2023 Jun 29; 15(3):3412. [Invited Review]

Gu Y, Low JM, Tan JSY, Ng MSF, Ng LFP, Shunmuganathan B, Gupta R, MacAry PA, Amin Z, Lee LY, Lian D, Shek LPC, Zhong Y, **Wang LW[†]**. Immune and pathophysiologic profiling of antenatal coronavirus disease 2019 in the GIFT cohort: A Singaporean case-control study. *Front Ped*. 2022 Sep 15; 10: 3389.

Low JM, Gu Y, Ng MSF, **Wang LW[†]**, Zubair A, Zhong Y, MacAry PA. Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern. *Vaccines*. 2022 Jan 31;10(2):225.

Low JM, Gu Y, Ng MSF, Amin Z, Lee LY, Ng YPM, Shunmuganathan B, Niu Y, Gupta R, Tambyah PA, MacAry P, **Wang LW[†]**, Zhong Y. Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees. *npj Vaccines*. 2021 Aug 19;6(105).